AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21478476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully-branded female packs
Number of subjects: 0
Study 21478476 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain packs
Number of subjects: 0
Study 21478476 — intervention group
Group type: COMPARATOR
Intervention: Non-female branded packs
Number of subjects: 0
Study 19222623 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 4 mg/kg once daily
Number of subjects: 0
Study 19222623 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin according to standard of care
Number of subjects: 0
Study 17139034 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence therapy
Number of subjects: 0
Study 17139034 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 0
Study 12624483 — intervention group
Group type: EXPERIMENTAL
Intervention: BT‐CoQ10 (300 mg daily for 1 week)
Number of subjects: 11
Study 12624483 — intervention group
Group type: COMPARATOR
Intervention: Commercial grade CoQ10 (300 mg daily for 1 week)
Number of subjects: 11
Study 11516000 — intervention group
Group type: EXPERIMENTAL
Intervention: Endopore dental implants
Number of subjects: 50
Study 9145132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (100% oxygen at 2.4 ATA, n = 6)
Number of subjects: 12
Study 9145132 — intervention group
Group type: COMPARATOR
Intervention: Control group (8.75% oxygen at 2.4 ATA, n = 6)
Number of subjects: 12
Study 8198274 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous lidocaine
Number of subjects: 0
Study 8198274 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg intravenous lidocaine
Number of subjects: 0
Study 3542470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazoline (Kefzol 0.5 g every six hours)
Number of subjects: 541
Study 3542470 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (Rocephin 2 g single dose)
Number of subjects: 541
Study 30241227 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant carboplatin and paclitaxel chemotherapy followed by radiotherapy
Number of subjects: 146
Study 27006549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg intravenously
Number of subjects: 90
Study 27006549 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg intravenously
Number of subjects: 90
Study 27006549 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 3 ml intravenously (placebo)
Number of subjects: 90
Study 25284808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 3426
Study 25284808 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 3426
Study 25284808 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate renal insufficiency (RI)
Number of subjects: 3426
Study 23900091 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium hydrate eye drops, 2 times/day for 10 days (low myopia) or 14 days (high myopia)
Number of subjects: 74
Study 23900091 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium hydrate eye drops
Number of subjects: 74
Study 23900091 — intervention group
Group type: COMPARATOR
Intervention: 0.1% fluorometholone eye drops, 4 times/day for 16 days
Number of subjects: 74
Study 21518967 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhii vaccination
Number of subjects: 351
Study 21518967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 21518967 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA levels
Number of subjects: 351
Study 21518967 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6 levels
Number of subjects: 351
Study 21518967 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA and interleukin 6 correlation
Number of subjects: 351
Study 21518967 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA and interleukin 6 levels
Number of subjects: 351
Study 17985084 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive warfarin dose reduction (10‐20%)
Number of subjects: 40
Study 17985084 — intervention group
Group type: COMPARATOR
Intervention: No change in warfarin dosing (Control)
Number of subjects: 40
Study 17985084 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive warfarin dose reduction (10‐20%) with TMP‐SMX
Number of subjects: 40
Study 17985084 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive warfarin dose reduction (10‐20%) with levofloxacin
Number of subjects: 40
Study 16513130 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who experienced the event four times with consistent suggestions
Number of subjects: 130
Study 16513130 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who experienced the event four times with inconsistent suggestions
Number of subjects: 130
Study 16513130 — intervention group
Group type: COMPARATOR
Intervention: Control group of children who experienced the event just one time
Number of subjects: 130
Study 16513130 — intervention group
Group type: EXPERIMENTAL
Intervention: Children encouraged to identify the source of false suggestions
Number of subjects: 130
Study 12679925 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2b interferon (3 MU/d)
Number of subjects: 48
Study 12679925 — intervention group
Group type: COMPARATOR
Intervention: Routine drugs (VitC, aspartic acid)
Number of subjects: 48
Study 10878680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (30 mg/day)
Number of subjects: 30
Study 10878680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8992906 — intervention group
Group type: COMPARATOR
Intervention: Conventional intubation (group KL)
Number of subjects: 120
Study 8992906 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachlight intubation (group TT)
Number of subjects: 120
Study 1400985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B reassortant virus vaccine (doses ranging from 10(3.2) to 10(6.2) TCID50)
Number of subjects: 63
Study 1400985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B reassortant virus vaccine
Number of subjects: 63
Study 1400985 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 63
Study 2943685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 13
Study 2943685 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13
Study 2943685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29133606 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass plus medical therapy
Number of subjects: 100
Study 29133606 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 100
Study 26931364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa Statement on the Ethical Design and Conduct of Cluster‐Randomized Trials
Number of subjects: 0
Study 26931364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials
Number of subjects: 0
Study 26931364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical analysis using the Ottawa Statement
Number of subjects: 0
Study 24885976 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIA intervention (implemented for six months)
Number of subjects: 36
Study 24885976 — intervention group
Group type: COMPARATOR
Intervention: Comparison facilities (no intervention)
Number of subjects: 36
Study 22386831 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/400 mg BID, 400 mg once daily
Number of subjects: 3588
Study 22386831 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg daily
Number of subjects: 3588
Study 22386831 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 800 mg daily
Number of subjects: 3588
Study 22386831 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin use
Number of subjects: 3588
Study 22386831 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 3588
Study 20299258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Number of subjects: 0
Study 18545189 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic resistance training (ERT) plus usual TKD training
Number of subjects: 12
Study 18545189 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual TKD training only
Number of subjects: 12
Study 17135986 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB (fluoxetine + cognitive-behavioral therapy)
Number of subjects: 439
Study 17135986 — intervention group
Group type: EXPERIMENTAL
Intervention: FLX (fluoxetine)
Number of subjects: 439
Study 17135986 — intervention group
Group type: COMPARATOR
Intervention: CBT (cognitive-behavioral therapy)
Number of subjects: 439
Study 12658672 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT with spouse involvement
Number of subjects: 94
Study 12658672 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group CBT
Number of subjects: 94
Study 12658672 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 94
Study 10733540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice per day) for 1 week
Number of subjects: 46
Study 10733540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 10733540 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 46
Study 8958194 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A
Number of subjects: 29
Study 8958194 — intervention group
Group type: EXPERIMENTAL
Intervention: Method SP
Number of subjects: 29
Study 8958194 — intervention group
Group type: EXPERIMENTAL
Intervention: Method SW
Number of subjects: 29
Study 1326405 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 1
Study 1326405 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1
Study 2866493 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 66
Study 2866493 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 66
Study 31277049 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU acquired Weakness (ICUaW) patients
Number of subjects: 36
Study 29076666 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Capsaicin
Number of subjects: 300
Study 29076666 — intervention group
Group type: COMPARATOR
Intervention: Topical Turpentine Oil
Number of subjects: 300
Study 26054444 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education booklet and telephone follow-ups
Number of subjects: 160
Study 26054444 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 23809982 — intervention group
Group type: EXPERIMENTAL
Intervention: SS + rSK 200,000 IU
Number of subjects: 80
Study 23809982 — intervention group
Group type: COMPARATOR
Intervention: SS
Number of subjects: 80
Study 23809982 — intervention group
Group type: EXPERIMENTAL
Intervention: SS + rSK 100,000 IU
Number of subjects: 80
Study 23809982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21639940 — intervention group
Group type: EXPERIMENTAL
Intervention: My Parenting SOS intervention (35-week program with 12 sessions focusing on parenting skills and promoting healthier eating and physical activity)
Number of subjects: 0
Study 21639940 — intervention group
Group type: EXPERIMENTAL
Intervention: My Parenting SOS intervention
Number of subjects: 0
Study 19349130 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbosylane (activated charcoal-simethicone combination)
Number of subjects: 132
Study 19349130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 16384767 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with epinephrine buffered with sodium bicarbonate
Number of subjects: 60
Study 16384767 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine freshly mixed with epinephrine
Number of subjects: 60
Study 12767537 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 100
Study 12767537 — intervention group
Group type: COMPARATOR
Intervention: Standard antiarrhythmics (Lidocaine and Amiodarone)
Number of subjects: 100
Study 12767537 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (subgroup analysis)
Number of subjects: 100
Study 11065207 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen (O2 group)
Number of subjects: 40
Study 11065207 — intervention group
Group type: COMPARATOR
Intervention: 33% oxygen in nitrous oxide (O2‐N2O group)
Number of subjects: 40
Study 9412397 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/potassium clavulanate (amoxyclav) 1.2 g IV every 8 hours for 2 days, then 625 mg orally thrice a day for 5 days
Number of subjects: 20
Study 9412397 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 1.0 g IM every 8 hours for 7 days
Number of subjects: 20
Study 8243427 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA type diet
Number of subjects: 37
Study 8243427 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 37
Study 2418292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg, intravenously)
Number of subjects: 10
Study 2418292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29764639 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based SP encounter via video conference
Number of subjects: 0
Study 29764639 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face SP encounter
Number of subjects: 0
Study 29764639 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based SP encounter
Number of subjects: 0
Study 28757108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine + Celastrol
Number of subjects: 626
Study 28757108 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine + Placebo
Number of subjects: 626
Study 25127927 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol session (.82 g/kg)
Number of subjects: 17
Study 25127927 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 17
Study 23458986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugared PEG solution
Number of subjects: 100
Study 23458986 — intervention group
Group type: COMPARATOR
Intervention: Standard PEG solution
Number of subjects: 100
Study 22003206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists' assessment of supportive care needs and symptoms
Number of subjects: 408
Study 22003206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists' assessment of physical symptoms
Number of subjects: 408
Study 22003206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists' assessment of borderline/clinical depression and anxiety
Number of subjects: 408
Study 18606533 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC250
Number of subjects: 476
Study 18606533 — intervention group
Group type: COMPARATOR
Intervention: SFC100
Number of subjects: 476
Study 18606533 — intervention group
Group type: COMPARATOR
Intervention: FP250
Number of subjects: 476
Study 16464715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MIBG imaging (H/M [d] <1.7)
Number of subjects: 144
Study 16464715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MIBG imaging (CAN diagnosed by H/M [d] and coefficient variance of RR interval)
Number of subjects: 144
Study 16464715 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up period of 7.2+/−3.2 years
Number of subjects: 144
Study 14564460 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic lycopene (Lycovit 10%, 15 mg/day for 28 days)
Number of subjects: 36
Study 14564460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato-based lycopene (Lyc-O-Mato, 15 mg/day for 28 days)
Number of subjects: 36
Study 14564460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without lycopene, 15 mg/day for 28 days)
Number of subjects: 36
Study 10670117 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg tramadol (Group T)
Number of subjects: 40
Study 10670117 — intervention group
Group type: COMPARATOR
Intervention: 3 micrograms/kg fentanyl (Group F)
Number of subjects: 40
Study 8965951 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of lymphocytes from the original bone marrow donor
Number of subjects: 28
Study 1365472 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen (500 mg b.d.)
Number of subjects: 100
Study 1365472 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac (50 mg t.i.d.)
Number of subjects: 100
Study 6883914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 2 mg/kg
Number of subjects: 45
Study 6883914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 3 mg/kg
Number of subjects: 45
Study 6883914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 5 mg/kg
Number of subjects: 45
Study 6883914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 10 mg/kg
Number of subjects: 45
Study 6883914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 15 mg/kg
Number of subjects: 45
Study 30239412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie facilitated intubation
Number of subjects: 3
Study 30239412 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airways (SGA)
Number of subjects: 3
Study 30239412 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 3
Study 26817643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic irradiation of tracts (PIT) with 21 Gy in three fractions
Number of subjects: 374
Study 26817643 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic irradiation of tracts (Control)
Number of subjects: 374
Study 24290286 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg twice daily for 3 months)
Number of subjects: 65
Study 24290286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 22180344 — intervention group
Group type: EXPERIMENTAL
Intervention: MAID/RT regimen (mesna, Adriamycin, ifosfamide, dacarbazine) with 3 cycles of preoperative chemotherapy and 44 Gy of RT followed by surgery and 3 cycles of postoperative MAID, with additional 16 Gy of RT for positive surgical margins.
Number of subjects: 48
Study 22180344 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical matched-control patients).
Number of subjects: 48
Study 20431612 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold diode laser photocoagulation (group A)
Number of subjects: 20
Study 20431612 — intervention group
Group type: COMPARATOR
Intervention: Threshold diode laser photocoagulation (group B)
Number of subjects: 20
Study 17962233 — intervention group
Group type: EXPERIMENTAL
Intervention: Negotiating individual blood pressure goals with patients
Number of subjects: 1534
Study 17962233 — intervention group
Group type: EXPERIMENTAL
Intervention: General population characteristics (e.g., gender, BMI, smoking status)
Number of subjects: 1534
Study 17962233 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and duration of diabetes
Number of subjects: 1534
Study 17962233 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive treatment
Number of subjects: 1534
Study 17962233 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 1534
Study 16199633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal descensus (anterior, posterior, and maximum)
Number of subjects: 270
Study 16199633 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing or feeling a bulge
Number of subjects: 270
Study 16199633 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive urinary symptoms
Number of subjects: 270
Study 16199633 — intervention group
Group type: COMPARATOR
Intervention: Urinary incontinence or bowel symptoms
Number of subjects: 270
Study 12016598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 22
Study 12016598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10516349 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (10 mg/kg intravenously at the end of each hemodialysis session for 4 months)
Number of subjects: 17
Study 10516349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously at the end of each hemodialysis session for 4 months)
Number of subjects: 17
Study 10516349 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (in vitro incubation)
Number of subjects: 17
Study 10516349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in vitro incubation)
Number of subjects: 17
Study 10516349 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 17
Study 10516349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8607053 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified peribulbar block
Number of subjects: 408
Study 8607053 — intervention group
Group type: COMPARATOR
Intervention: Standard retrobulbar block combined with facial nerve block of the O'Brien type
Number of subjects: 408
Study 1804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I: daily single-dose treatment with 200 mg of ofloxacin
Number of subjects: 51
Study 1804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II: every two week multidose treatment with 3 x 200 mg/day of ofloxacin
Number of subjects: 51
Study 7068895 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal treatment
Number of subjects: 10
Study 7068895 — intervention group
Group type: COMPARATOR
Intervention: Negative practice treatment
Number of subjects: 10
Study 31090440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral posterior quadratus lumborum blockade with 25-30 mL of 0.25% levobupivacaine
Number of subjects: 60
Study 31090440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 60
Study 31090440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral posterior quadratus lumborum blockade
Number of subjects: 60
Study 29423410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) administered intravenously during surgery
Number of subjects: 60
Study 26372470 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication monitor
Number of subjects: 4173
Study 26372470 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (medication monitor + text messaging)
Number of subjects: 4173
Study 26372470 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 4173